原发性高血压患者中G蛋白β3亚单位基因C825T多态性与复方缬沙坦降压疗效的相关性

Relationship between G-protein β3 gene C825T polymorphism and antihypertensive effect of valsartan/hydrochlorothiazide in patients with essential hypertension

目的:探讨原发性高血压(EH)患者中G蛋白β3亚单位基因C825T多态性与EH发生,及复方缬沙坦降压疗效的相关性。方法:80例EH患者(EH组)给予复方缬沙坦1粒/d,治疗4周后,观察其降压疗效。应用直接测序方法对EH组患者和40名健康者(对照组)G蛋白β3亚单位基因C825T作基因分型。结果:EH组中CC和CT+TT基因型频率分别为31.25%和68.75%,对照组中分别为52.50%和47.50%,2组间CT+TT基因型频率差异有统计学意义(P<0.05)。EH组中C和T等位基因频率分别为41.88%和58.12%,对照组中分别为57.50%和42.50%,2组间T等位基因频率差异有统计学意义(P<0.05)。EH组患者中,复方缬沙坦对携带T等位基因者血压的下降幅度与携带C等位基因者比较差异有统计学意义(P<0.05)。结论:G蛋白β3亚单位基因C825T多态性与EH发病有关,携带T等位基因者可能是缬沙坦降压疗效的新的预测因子。

Objective：To explore the relationship between G-protein β3（GNB3） gene C825T and antihypertensive response to valsartan/hydrochlorothiazide in patients with essential hypertension（EH）. Method：Eighty EH patients（EH group） were received valsartan/hydrochlorothiazide one tablet once daily for four weeks.Direct DNA sequencing was performed to detect the signgle nucleotide polymorphisms of GNB3 gene C825T in patients with EH and forty normal blood pressure controls（control group）. Result：The frequencies of genotype（CC and CT＋TT） were 31.25%,68.75% in EH group and 52.50%,47.50% in control group respectively.There was significant difference in frequencies of CT＋TT between the two groups（P〈0.05）.The allele frequencies of C and T were 41.88%,58.12% in EH group and 57.50%,42.50% in control group respectively.The allele frequencies of T has significant difference between the two groups（P〈0.05）.Treated with valsartan/hydrochlorothiazide,patients with T allele had greater reduction in blood pressure compared to those with C allele（P〈0.05）. Conclusion：GNB3 gene C825T polymorphism may be involved in the development of EH,and patients who carried T allele may be a new predictor for antihypertensive efficacy of valsartan/hydrochlorothiazide.